dr. pegram discusses challenges once biosimilars hit us market
Published 5 years ago • 81 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
1:40
dr. pegram on the manufacturing process of biosimilars
-
1:41
dr. pegram on the development of trastuzumab biosimilars
-
1:51
dr. pegram on future impact of biosimilars in oncology
-
1:22
dr. pegram on projections of cost reductions with biosimilars
-
1:44
dr. schmid on challenges concerning biosimilars in oncology
-
3:35
epigenomics in precision oncology
-
29:07
silicon valley's hc bets: cancer diagnostics and the human genome
-
4:20
the biosimilar development process
-
3:57
challenges in biosimilar acceptance
-
2:21
what are biosimilars?
-
0:35
biosimilars market size to hit usd 136,069.53 million by 2028
-
2:56
biosimilars knocking doors of ophthalmology -video abstract - [id 180393]
-
2:14
dr. pegram on sequencing therapies in her2-positive breast cancer
-
4:38
biosimilars and the exciting results of the reflections trial
-
3:07
the future of predicting outcomes for patients with mpns: a patient knowledge bank
-
2:37
the epigenomics of myeloma
-
5:56
the complexity of choosing biosimilars in oncology
-
4:47
dr jacek mokrosinski from the university of cambridge describes the using nanobit® for gpcr research
-
1:31
evolution, not revolution: the acceptance of biosimilars by practicing clinicians
-
1:05
the prognostic and potentially therapeutic value of liquid biopsy in multiple myeloma
-
1:58
versiti | hematology genomics - diagnostic labs
-
2:58
apobec enzymes contribute to cancer mutagenesis